NEW YORK, July 16, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Acorda Therapeutics, Inc. (NASDAQ: ACOR), and Repros Therapeutics Inc. (NASDAQ: RPRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Celgene Corporation Research Report
On July 11, 2013, Celgene Corporation's (Celgene) wholly-owned subsidiary, Celgene International Sàrl, announced that it has met the primary endpoint of progression-free survival (PFS) for its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma. Celgene reported that a statistically significant improvement in PFS was seen during the study through a doublet regimen of continuous oral lenalidomide in combination with low-dose dexamethasone (Rd), compared to patients receiving a comparator arm with a triplet regimen consisting of melphalan, prednisone and thalidomide (MPT). The Company stated that it will commence its discussions with regulatory authorities based on the Front-Line Investigation of REVLIMID/Dexamethasone vs. Standard Thalidomide (FIRST). Celgene also reported that its subsidiary has existing plans to submit dossiers for registration in the US, Europe, and other markets. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/7541_CELG]
Alnylam Pharmaceuticals, Inc. Research Report
On July 11, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced positive top-line results from its ongoing Phase I trial of ALN-TTRsc. ALN-TTRsc is a subcutaneously administered RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). Alnylam reported that ALN-TTRsc achieved robust and statistically significant (p<0.01) knockdown of serum TTR protein levels of greater than 80% in healthy volunteer subjects, in line with results for ALN-TTRsc previously reported in non-human primates. John Maraganore, Ph.D., CEO of Alnylam, said, "These clinical results with ALN-TTRsc establish human translation for RNAi therapeutics that utilize our GalNAc-siRNA conjugate delivery platform. This platform enables subcutaneous dose administration with a wide therapeutic index and has now become our primary approach for development of RNAi therapeutics. As a result, we believe these data are very meaningful not only for the continued advancement of ALN-TTRsc, but also for the continued execution on our entire 'Alnylam 5x15' product strategy." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/5328_ALNY]
Questcor Pharmaceuticals, Inc. Research Report
On July 11, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that it is planning to initiate a pilot commercialization effort for H.P. Acthar Gel (repository corticotropin injection) for the treatment of respiratory manifestations of symptomatic sarcoidosis, a potentially serious, difficult-to-treat disorder already included on the FDA-approved package insert for Acthar. According to Questcor, its pilot commercialization effort will focus on pulmonologists, who are the respiratory specialists treating this rare autoimmune disorder. Don M. Bailey, President and CEO of Questcor, commented, "This commercial expansion, together with our increasing R&D investment, continues our efforts to expand patient access to the FDA-approved, on-label indications of Acthar." Bailey added, "Already, patients suffering from nephrotic syndrome (NS), multiple sclerosis (MS) exacerbations, infantile spasms, and certain rheumatology-related conditions have benefitted from Acthar. Our plans to increase awareness among pulmonologists treating patients suffering from respiratory manifestations of symptomatic sarcoidosis will follow the model we have used successfully for these other markets as we continue to explore the full therapeutic potential of Acthar." The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/ad11_QCOR]
Acorda Therapeutics, Inc. Research Report
On July 9, 2013, Acorda Therapeutics, Inc. (Acorda) announced the acquisition of two neuropathic pain management assets from NeurogesX, Inc., which include Qutenza, an FDA-approved therapy for the management of neuropathic pain associated with postherpetic neuralgia; and NP-1998, a Phase III-ready, prescription strength capsaicin topical solution, being assessed for the treatment of neuropathic pain. Ron Cohen, M.D., President and CEO of Acorda, stated, "The acquisition of Qutenza and NP-1998 enables us to expand into the area of neuropathic pain management. We plan to support Qutenza with our existing medical and commercial infrastructure, which includes one of the industry's best neurology sales forces." Cohen continued, "In addition, we will leverage our neurology expertise to evaluate NP-1998 for the treatment of neuropathic pain, with an initial emphasis on painful diabetic neuropathy. This adds another potentially important, late stage product to our pipeline." The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/de76_ACOR]
Repros Therapeutics Inc. Research Report
On July 9, 2013, Repros Therapeutics Inc. (Repros) announced the formation of an international, multi-disciplinary, clinical advisory board to help maximize the commercial opportunity for Androxal. The Company's management and the Board of Directors have reportedly taken steps to assemble a well-rounded and effective group of Key Opinion Leaders to begin the multi-disciplinary patient and physician education process that should have great utility for the Company independent of the eventual Androxal commercial strategy. Mike Wyllie, Director of Repros, said, "I am pleased with the enthusiasm to participate and the quality and diversity of our advisory board. It is important to prepare for the arrival of an effective oral therapy for the treatment of secondary hypogonadism and provide the right support for patients and providers." The Full Research Report on Repros Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/2939_RPRX]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Wall Street Reports